{
    "MBG.F": {
        "short_name": "MARINOMED BIOTECH AG INH.",
        "long_name": "Marinomed Biotech AG",
        "summary": "Marinomed Biotech AG, a biopharmaceutical company, develops products for respiratory and ophthalmological diseases in Austria, other European countries, and internationally. It operates in two segments, Marinosolv and Carragelose. The company develops its products based on the Marinosolv, a technology platform that enhances the bioavailability of hardly soluble compounds for the treatment of sensitive tissues, such as nose and eyes; and Carragelose, an antiviral respiratory technology platform. It offers nasal and throat sprays, and lozenges. The company is also developing Budesolv and Tacrosolv targeting inflammatory diseases of nose and eyes. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was founded in 2006 and is headquartered in Vienna, Austria.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Austria",
        "city": "Vienna"
    }
}